ImmunityBio SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KNov. 9, 2026, 7:39 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedImmunityBio Q3 2026 Net Product Revenue of $48.7 Million Up 53% Year-Over-Year, Below $59.2 Million Consensus; Adjusted Loss of $0.09 Per Share vs $0.05 Expected
8-KNov. 9, 2026, 6:33 a.m. ETView on SEC.gov
Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedImmunityBio Says ANKTIVA Plus BCG Met Primary Endpoint in BCG-Naïve NMIBC Phase QUILT-2.005 Trial; sBLA Planned by Year-End 2026
8-KOct. 14, 2026, 5:19 p.m. ETView on SEC.gov
Regulation FD disclosure · Financial statements and exhibits
8-KAug. 4, 2026, 7:36 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
8-KJuly 30, 2026, 5:19 p.m. ETView on SEC.gov
Regulation FD disclosure · Financial statements and exhibits